Fisher & Paykel Shares Lead ASX 200, as Margins Prove Resilient

Fisher & Paykel shares (ASX: FPH) jumped sharply on Tuesday, adding 9.15% after the company demonstrated it can absorb ongoing cost pressures while maintaining its path toward industry-leading profitability margins.

The FPH share price ended the day back above A$30, closing at A$30.05, and recouping more than half of its year-to-date decline, now lower by 7.11% for 2026. The rally came after the company released its full-year FY26 results alongside FY27 guidance that reassured markets about both earnings momentum and margin trajectory despite persistent external headwinds.

The move represents a significant sentiment shift for a stock that had been weighed down by concerns over tariff impacts, hardware demand normalisation, and post-pandemic growth sustainability, with FPH leading all ASX 200 gainers today.

Fundamentals Support Bounce in FPH Shares

Fisher & Paykel Healthcare reported net profit after tax of approximately NZ$468.5 million for FY26, representing growth of roughly 24% year-on-year. The result came in at the upper end of the company’s most recent upgraded guidance range and was accompanied by an increased final dividend, reflecting management’s confidence in cash generation and balance sheet strength.

Revenue performance was driven by continued strong demand across the company’s hospital product portfolio, particularly in consumables and obstructive sleep apnea masks. The result validated the February 2026 guidance upgrade, when management had lifted revenue expectations to around NZ$2.30 billion and NPAT to NZ$450–470 million, citing good growth across the full range of hospital products and benefits from continuous improvement initiatives.

For FY27, the company issued guidance for revenue of NZ$2.45–2.57 billion and NPAT of NZ$500–550 million, indicating another year of solid growth off an already elevated base. Management expects hospital consumables and OSA masks to grow at rates similar to FY26, while hardware sales which had benefited from two strong years of US demand for Airvo 3 and 950 systems may be flat or decline as the replacement cycle normalises.

The company provided detailed commentary on gross margin dynamics that directly addressed one of the market’s primary concerns. For FY27, Fisher & Paykel expects a net headwind of approximately 50 basis points from tariffs and Middle East logistics surcharges, comprising roughly 70 basis points of drag from US tariffs, 45 basis points from raw materials, and 25 basis points from freight costs.

Critically, management expects to fully offset these pressures through approximately 50 basis points of improvement from continuous improvement and efficiency initiatives. This framework demonstrates that the company’s operational excellence programmes are delivering tangible results in real time, rather than remaining aspirational targets.

Looking further ahead, Fisher & Paykel reiterated its target of achieving a 65% gross margin within two to three years if current conditions persist, with 67–68% achievable under more favourable foreign exchange conditions. The company expects to deliver 100–150 basis points of annual margin improvement from business initiatives, providing a clear self-help pathway independent of external factors.

Fast-Growing Segment

One of the more notable disclosures in the update was the performance of Fisher & Paykel’s anesthesia product line, which is growing at more than 40% annually and now accounts for over 10% of new applications revenue. Management noted that anesthesia products are penetrating clinical practice slightly faster than high-flow respiratory products did historically, suggesting a potentially larger long-term opportunity.

The anesthesia growth represents an important diversification of the company’s revenue base beyond its core high-flow therapy and OSA franchises. New applications consumables have been a key growth driver in recent years, and the acceleration in anesthesia validates Fisher & Paykel’s strategy of leveraging its core humidification and respiratory technologies into adjacent clinical settings.

This product mix evolution also supports the margin expansion story, as consumables typically carry higher gross margins than hardware and create recurring revenue streams as clinical adoption broadens.

What Lay Ahead

Looking ahead, Fisher & Paykel faces a relatively clear pathway to continued earnings growth and margin expansion, underpinned by structural drivers including aging demographics, increasing prevalence of respiratory and sleep disorders, and ongoing clinical adoption of its technologies in new applications.

From a valuation perspective, today’s 9% bounce in FPH shares has compressed some of the margin of safety that existed after the earlier year-to-date decline. While Fisher & Paykel remains a high-quality franchise, those entering at current levels are paying up for execution on the margin expansion roadmap and sustained consumables growth, leaving less room for disappointment.